Literature DB >> 27178687

Cutaneous manifestations of genitourinary malignancy.

Derek Raghavan1.   

Abstract

Genitourinary cancers are associated with a range of cutaneous syndromes, which can reflect direct metastatic spread, non-metastatic manifestations of malignancy or the consequences of treatment. More than 220,000 new cases of prostate cancer occur each year in the United States, and thus the associations with cutaneous involvement are quite well documented-rare metastatic spread, vasculitic and hemorrhagic syndromes. Cancers of the bladder and kidney may be associated with direct cutaneous metastases, vasculitic syndromes, hereditary leiomyomatosis, and other familial syndromes. Testicular cancer occasionally metastasizes to the skin but more commonly is associated with the dysplastic nevus (multiple atypical nevus) syndrome. A structured approach to history-taking, examination, and investigation is essential for optimal management, especially when these syndromes precede the diagnosis of a known malignancy. A brief review of the more common iatrogenic cutaneous complications is provided, and includes Raynaud's phenomenon, purpura, rash, hand-foot syndrome, the consequences of marrow failure, and bleomycin-induced pigmentation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder; Genitourinary; Germ cell; Prostate; Renal cell; Testis

Mesh:

Year:  2016        PMID: 27178687     DOI: 10.1053/j.seminoncol.2016.02.027

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  CAN SKIN BE A MARKER FOR INTERNAL MALIGNANCY? EVIDENCE FROM CLINICAL CASES.

Authors:  Liborija Lugović-Mihić; Mirela Krišto; Sanja Špoljar; Gaby Novak-Bilić; Iva Bešlić; Majda Vučić; Mirna Šitum
Journal:  Acta Clin Croat       Date:  2021-12       Impact factor: 0.932

2.  Metastatic urothelial carcinoma.

Authors:  Elisabeth Gómez-Moyano; Silvestre Martínez Garcia; David Hernandez Alcaraz; Maria Ayala-Blanca
Journal:  An Bras Dermatol       Date:  2021-05-24       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.